Serum hepatitis B surface antigen levels predict treatment response to nucleos(t)ide analogues

Table 3 Hepatitis B surface antigen predict hepatitis B surface antigen loss during nucleos(t)ide analogues therapy

NAs	Treatment duration	Case number	Condition of HBsAg predict HBsAg loss	Ref.
Telbivudine	more than 3 yr	162 HBeAg (+)	HBsAg decline ≥ 1 log after 1 yr of treatment	[50]
Tenofovir	3 yr	263 HBeAg (+)	Steeper declines in HBsAg (-2.41 log10 IU/mL vs -0.20 log10 IU/mL) at month 6	[51]
Tenofovir	6 yr	104 HBV + HIV	HBsAg decline ≥ 2 log IU/mL at month 6	[36]
Lamivudine	more than 10 yr	70	Baseline HBsAg < 1000 IU/mL and on-treatment reduction of HBsAg > 0.166 log IU/mL per year	[38]
Lamivudine as their first drug	9 yr	791	HBeAg (+) patients: HBsAg decline ≥ 0.5 log IU/mL within 6 mo	[53]
			HBeAg (-) patients: HBsAg decline at 6 mo and baseline HBsAg levels of < 730 IU/mL

NAs: Nucleos(t)ide analogues; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; HBV: Hepatitis B virus; HIV: Human immunodeficiency virus.